Evolving Role of Gene Expression Signatures as Biomarkers in Early-Stage Colon Cancer

Journal of Gastrointestinal Cancer

Volumn 45, Issue 4, 2014, Pages 399-404

  Goel, Gaurav ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant chemotherapy; Biomarkers; ColoPrint; Colorectal cancer; Microsatellite instability; Oncotype DX; Recurrence score; Stage II colon cancer; Stage III colon cancer

Indexed keywords

BIOLOGICAL MARKER; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CANCER THERAPY; CHROMOSOMAL INSTABILITY; CLINICAL PRACTICE; COLON CANCER; COLORECTAL CANCER; GENE EXPRESSION PROFILING; GENE EXPRESSION SYSTEM; HUMAN; MICROSATELLITE INSTABILITY; RECURRENCE RISK; REVIEW; TUMOR RECURRENCE; UNITED STATES; COLONIC NEOPLASMS; GENETICS; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84914106069     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-014-9634-7     Document Type: Review

References (32)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.
3. Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, et al. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res. 2001;61:818–22.
4. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.
5. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717–22.
6. Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer. 1998;79:390–5.
7. Fishel R. Mismatch repair, molecular switches, and signal transduction. Genes Dev. 1998;12:2096–101.
8. Lanza G, Gafa R, Maestri I, Santini A, Matteuzzi M, et al. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol. 2002;15:741–9.
9. Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, et al. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol. 2006;30:1175–83.
10. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.
11. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 2008;61:561–9.
12. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.
13. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.
14. Benson 3rd AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.
15. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–7.
16. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009 11: 35–41.
17. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.
18. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.
19. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 2003;22:9192–6.
20. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151–6.
21. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.
22. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.
23. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.
24. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768–74.
25. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, etal. (2010) AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition. Springer, New York. p. 143.
26. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.
27. Salazar R, Roepman P, Capella G, Moreno V, Simon I, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29:17–24.
28. Salazar R, Tabernero J, Moreno V, Nitsche U Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients. J Clin Oncol 2012; 30:abstract 3510.
29. O’Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937–44.
30. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29:4611–9.
31. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31:1775–81.
32. Yothers G, O’Connell MJ, Lee M, Lopatin M, Clark-Langone KM, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31:4512–9.